- Home
- CMMB vs BCDA Comparison
CMMB vs BCDA Comparison
Compare CMMB & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- BCDA
- Stock Information
- Founded
- CMMB 2004
- BCDA N/A
- Country
- CMMB Israel
- BCDA United States
- Employees
- CMMB N/A
- BCDA N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- BCDA Health Care
- Exchange
- CMMB Nasdaq
- BCDA Nasdaq
- Market Cap
- CMMB 13.7M
- BCDA 11.3M
- IPO Year
- CMMB N/A
- BCDA N/A
- Fundamental
- Price
- CMMB $2.58
- BCDA $1.29
- Analyst Decision
- CMMB Strong Buy
- BCDA Strong Buy
- Analyst Count
- CMMB 2
- BCDA 1
- Target Price
- CMMB $26.50
- BCDA $25.00
- AVG Volume (30 Days)
- CMMB 151.5K
- BCDA 182.7K
- Earning Date
- CMMB 11-12-2025
- BCDA 11-12-2025
- Dividend Yield
- CMMB N/A
- BCDA N/A
- EPS Growth
- CMMB N/A
- BCDA N/A
- EPS
- CMMB N/A
- BCDA N/A
- Revenue
- CMMB N/A
- BCDA N/A
- Revenue This Year
- CMMB N/A
- BCDA N/A
- Revenue Next Year
- CMMB N/A
- BCDA N/A
- P/E Ratio
- CMMB N/A
- BCDA N/A
- Revenue Growth
- CMMB N/A
- BCDA N/A
- 52 Week Low
- CMMB $2.39
- BCDA $1.00
- 52 Week High
- CMMB $9.84
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- CMMB 38.12
- BCDA 41.21
- Support Level
- CMMB $2.95
- BCDA $1.27
- Resistance Level
- CMMB $2.80
- BCDA $1.45
- Average True Range (ATR)
- CMMB 0.26
- BCDA 0.09
- MACD
- CMMB -0.09
- BCDA 0.00
- Stochastic Oscillator
- CMMB 2.30
- BCDA 14.81
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).